N-[4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1H-1-benzazepine-1-carbonyl)-3-methylphenyl]-2-methylbenzamide

• ChemBase编号: 73268
• 分子式: C26H25ClN2O3
• 平均质量: 448.9413
• 单一同位素质量: 448.15537035
• SMILES: C(=O)(c1c(cc(cc1)NC(=O)c1ccccc1C)C)N1CCCC(c2c1ccc(c2)Cl)O
• Canonical SMILES: Clc1ccc2c(c1)C(O)CCCN2C(=O)c1ccc(cc1C)NC(=O)c1ccccc1C
• InChI: InChI=1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31)
• InChIKey: GYHCTFXIZSNGJT-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: N-[4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1H-1-benzazepine-1-carbonyl)-3-methylphenyl]-2-methylbenzamide
• IUPAC传统名: tolvaptan; N-[4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)-3-methylphenyl]-2-methylbenzamide
• 别名: N-(4-(7-Chloro-5-hydroxy-2,3,4,5-tetrahydro-1H-benzo[b]azepine-1-carbonyl)-3-methylphenyl)-2-methylbenzamide; N-[4-[(7-Chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methylbenzamide; OPC 41061; Tolvaptan; OPC-41061; Samsca; Tolvaptan

登记号

• CAS号: 150683-30-0
• MDL号: MFCD09838782
• PubChem SID: 162038188
• PubChem CID: 216237

理论计算性质

• Acid pKa: 11.755283
• 质子受体: 3
• 质子供体: 2
• LogD (pH = 5.5): 5.3501835
• LogD (pH = 7.4): 5.3501654
• Log P: 5.3501835
• 摩尔折射率: 129.1552 cm^3
• 极化性: 48.183975 Å^3
• 极化表面积: 69.64 Å^2
• 可自由旋转的化学键: 3
• 里宾斯基五规则: false

分子性质

理化性质

• 溶解度: DMSO: ≥15 mg/mL; Methanol
• 外观: White Solid; white to tan powder
• 熔点: 219-222°C

安全信息

• 保存条件: -20°C; Refrigerator
• 德国WGK号: 3
• 保存温度: 2-8°C

产品相关信息

• 纯度: ≥98% (HPLC); 95+%
• 成盐信息: Free Base
• Empirical Formula (Hill Notation): C26H25ClN2O3

详细说明

Selleck Chemicals - S2593

Biological Activity:
Tolvaptan (OPC-41061) is a selective, competitive arginine vasopressin receptor 2 antagonist with an IC50 of 1.28µM for the inhibition of AVP-induced platelet aggregation. Tolvaptan (OPC-41061) is used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH). Tolvaptan (OPC-41061) is also in fast-track clinical trials for polycystic kidney disease. Treatment with t tolvaptan (OPC-41061) causes rapid and sustained body weight reductions concurrent with increases in urine output, improves and/or normalizes serum sodium in hyponatremic patients, reduces signs and symptoms of congestion and increases thirst. However, tolvaptan (OPC-41061) has not been shown to decrease heart failure re-hospitalization or mortality. As an adjunct to standard therapy, tolvaptan (OPC-41061) is unique in that it is virtually the only novel agent tested in patients hospitalized for acute heart failure syndrome (AHFS) to reach its primary end point for short-term efficacy without causing deleterious side effects. [1][2][3]References on Tolvaptan (OPC-41061)[1] http://en.wikipedia.org/wiki/Tolvaptan, , [2] Eur J Endocrinol. , 2011 Feb 11, [3] Expert Opin Pharmacother., 2011 Apr, 12(6):961-76

Sigma Aldrich - T7455

Biochem/physiol Actions
Tolvaptan (OPC 41061) is a potent, orally active non-peptide vasopressin V2 selective antagonist. IC50 = 3 nM at the rat V2 receptor; 29 times more selective for the V2 than for V1a. Tolvaptan has also been shown to inhibit the development of polycystic kidney disease in several animal models.

Toronto Research Chemicals - T536650

It is a selective, competitive arginine vasopressin V2 receptor antagonist used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH).

参考文献

• Paterna, S., et al.: Eur. J. Heart Fail, 2, 305 (2000)
• Udelson, J., et al.: Circulation, 104, 2417 (2000)
• Goldsmith, S., et al.: J. Am. Coll Cardiol., 46, 1785 (2000)
• Schrier, R., et al.: N. Engl. J. Med., 355, 2099 (2000)